Chronic oral haloperidol and clozapine in rats: A behavioral evaluation

Neuropsychobiology

Volumn 39, Issue 2, 1999, Pages 86-91

  Schmitt, Ulrich ^b   Dahmen, Norbert ^b   Fischer, Viola ^b   Weigmann, Harald ^b   Rao, Marie Luise ^b   Reuss, Stefan ^b   Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NONE

Author keywords

Behavior; Blood plasma levels; Chronical treatment; Clozapine; Haloperidol; Locomotion; Rat

Indexed keywords

CLOZAPINE; DRINKING WATER; HALOPERIDOL;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BLOOD ANALYSIS; CONTROLLED STUDY; FEMALE; HABITUATION; LONG TERM CARE; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RAT; SERUM;

EID: 0032983749     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026566     Document Type: Article

References (32)

1. Janssen PAJ, van de Westeringh C, Jagenau AHM, DeMoen PAJ, Hermans BKF, van Daele GHP, Schellekens KHL, van der Eycken CAM, Niemegeers CJE: Chemistry and pharmacology of CNS depressants related to 4-(4-hydroxy-4-phenylpiperidino)-butyrophenone. Part 1: Synthesis acid screening data in mice. J Med Pharm Chem 1959;1:281-297.
2. Kerwin RW: The new atypical antipsychotics. Br J Psychiatry 1994;164:141-148.
3. Settle EC Jr, Ayd FJ Jr: Haloperidol: A quarter century of experience. J Clin Psychiatry 1983; 44:440-448.
4. Weiner I, Shadach E, Tarrasch R, Kidron R, Feldon J: The latent inhibition model of schizophrenia: Further validation using the atypical neuroleptic, clozapine. Biol Psychiatry 1996;40:834-843.
5. Leysen JE, Janssen P, Gommeren W, Wynants J, Pauwels PJ, Janssen PAJ: In vitro and in vivo binding and effects on monoamine turn-over in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 1992;41:494-508.
6. Nielsen EB, Andersen PH: Dopamme receptor occupancy in vivo: Behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists. Eur J Pharmacol 1992;219:35-44.
7. Bartholini G: Differential effects of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic systems. J Pharm Pharmacol 1976;28:429-433.
8. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW: Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992;340:199-202.
9. van Tol HH, Brunzow JR, Guan HC, Sunahara RK, Seaman P, Niznik HB, Civelli O: Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614.
10. Carnoy P, Ravard S, Wemerman B, Soubrie P, Simon P: Behavioral deficits induced by low doses of apomorphine in rats: Evidence for a motivational and cognitive dysfunction which discriminates among neuroleptic drugs. Pharmacol Biochem Behav 1986;25:503-509.
11. Conceicao IM, Frussa-Filho R: Effects of microgram doses of haloperidol on open-field behavior in mice. Pharmacol Biochem Behav 1996;53:833-838.
12. Kovacs GL, de Wied D: Effects of amphetamine and haloperidol on avoidance behavior and exploratory activity. Eur J Pharmacol 1978;53:103-107.
13. Niemegeers CJE, Verbruggen FJ, Janssen PAJ: The influence of various neuroleptic drugs on shock avoidance responding in rats. Psychopharmacology 1969;16:161-174.
14. Rodriguez R: Effects of various psychotropic drugs on the performance of avoidance and escape behaviors in rats. Pharmacol Biochem Behav 1992;43:1155-1159.
15. Stahle L, Ungerstedt U: Effects of neuroleptic drugs on the inhibition of exploratory behavior induced by a low dose of apomorphine: Implications for the identity of dopamine receptors. Pharmacol Biochem Behav 1986;25:473-480.
16. Rupniak NM, Hall MD, Mann S, Fleminger S, Kilpatrick G, Jenner P, Marsden CD: Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochem Pharmacol 1985; 34:2755-2763.
17. Waddington JL, Gamble SJ: Spontaneous activity and apomorphine stereotypy during and after withdrawal from 3.5 month continuous administration of haloperidol: Some methodological issues. Psychopharmacology 1980;71: 75-77.
18. Waddinglon JL, Gamble SJ: Neuroleptic treatment for a substantial proportion of adult life: Behavioral sequelae of 9 month haloperidol administration. Eur J Pharmacol 1980;67:363-369.
19. Rao ML: Modification of the radioreceptor assay technique for estimation of serum neuroleptic drug levels leads to improved precision and sensitivity. Psychopharmacology 1986;90: 548-553.
20. Weigmann H, Bierbrauer J, HärtterS, Hiemke C: Automated determination of clozapine and major metabolites in serum and urine. Ther Drug Monit 1997;19:480-488.
21. Schmitt U, Hiemke C: Strain differences in open-field and elevated plus-maze behavior of rats without and with pretest handling. Pharmacol Biochem Behav 1998;59:807-811.
22. Bell WJ: Searching Behavior: The Behavioral Ecology of Finding Recourses. London, Chapman * Hall, 1991.
23. van Putten T, Marder SR, Mintz J, Poland RE: Haloperidol plasma levels and clinical response: A therapeutic window relationship. Am J Psychiatry 1992;149:500-505.
24. Hasegawa M, Gutierrez-Esteinou R, Way I, Meltzer HY: Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking. J Clin Psychopharmacol 1993;13:383-390.
25. Perry PJ, Miller DD, Arndt SV, Cadoret RJ: Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991;148:231-235.
26. Lynch MR: Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol. Neuropsychobiology 1990-1991;24: 102-108.
27. Bunsey MD, Sanberg PR: The topography of the locomotor effects of haloperidol and domperidone. Behav Brain Res 1986;19:147-152.
28. Paulus MP, Geyer MA: A scaling approach to find order parameters quantifying the effects of dopaminergic agents on unconditioned motor activity in rats. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:903-919.
29. Lynch MR, Carey RJ: Environmental stimulation promotes recovery from haloperidol-induced extinction of open field behavior in rats. Psychopharmacology (Berl) 1987;92:206-209.
30. Ferre S. Prat G, Guix T, Goma M, Jane F, Casas M: T-maze performance in rats following chronic neuroleptic treatment. Pharmacol Biochem Behav 1990;35:481-484.
31. Costall B, Naylor RJ: Detection of the neuroleptic properties of clozapine. sulpiride and thioridazine were determined in the rat and compared with the responses of typical neuroleptic agents, haloperidol, fluphenanzine and pimozide. Psychopharmacology 1975;43:69-74.
32. Belesini DB, Jovanovic-Micic D, Japundzic N, Terzic AM, Samardzic R: Behavioral, autonom ic and motor effects of neuroleptic drugs in cats: Motor impairment and aggression. Brain Res Bull 1985;15:353-356.